Myeloid Growth Factor Support for Dose-Dense Adjuvant Chemotherapy for Breast Cancer
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor - ScienceDirect
外科 - dose - dense - EC - 乳腺 - q2w
Standard vs dose-dense adjuvant chemotherapy in hormone... | Download Scientific Diagram
Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer - Cancer Therapy Advisor
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar
Dose Dense-Intensive Chemotherapy Improves Survival in Early Stage Breast Cancer - CancerConnect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. | Semantic Scholar
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers' experience | Semantic Scholar
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - ScienceDirect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
